The Citizens Commission on Human Rights (CCHR) is urging consumers to read the labeling of psychotropic prescription drugs for warnings about suicide, aggression, and homicidal ideation, and to ask their prescribing physicians to explain these risks, even when they are listed as rare. This call follows recent news reports of violent crimes allegedly committed by individuals taking or withdrawing from prescribed antidepressants, stimulants, or other psychiatric drugs known to have side effects of aggression, homicidal ideation, and suicidal thoughts.
CCHR emphasizes that while drug regulators and manufacturers have required warnings on some of these drugs, the existence of a warning in the labeling does not guarantee that patients are adequately informed. Jan Eastgate, president of CCHR International, stated: "A rare warning buried in a package insert is not the same as a doctor explaining the risk to a patient. Listing a side effect as 'rare' does not establish that the patient was told about it, understood it, or agreed to take that risk. Meaningful informed consent requires meaningful disclosure and prescriber accountability."
The issue is gaining attention in both legal and psychiatric circles. A recent article in Psychiatric Times discussed whether psychiatrists should be held responsible for their patients' criminal behavior when psychiatric polypharmacy is a contributing factor. The article, titled "Psychiatry on Trial: Are Psychiatrists Responsible for Their Patients' Criminal Behavior?," noted that "a good portion of the public and the media appear to support the defense theory" in a high-profile murder case, and concluded that "psychiatry itself may end up on trial."
Legal doctrines such as involuntary intoxication may apply when prescribed drugs are alleged to have induced violent behavior, but its applicability depends on whether the drug was taken as prescribed and whether the person knew of the potential behavioral effects. Eastgate noted: "A judge allowing a jury to hear evidence about prescription drugs is not the same as a physician warning a patient before the first dose."
The concern is not new. In December 2005, Psychiatric Times published an article on psychopharmacology liability, referencing the FDA's 2004 public health advisory on antidepressants, which reported anxiety, agitation, panic attacks, insomnia, irritability, hostility, aggressiveness, impulsivity, akathisia (severe restlessness), hypomania, and mania in adults and children. In October 2004, the FDA mandated a boxed warning on antidepressants regarding suicidality in children and adolescents, later expanded to young adults.
CCHR's compilation of international regulatory agency warnings shows a dramatic increase in safety notices related to violence, aggression, or hostility: 57 since 2004, compared to just five in 2004, a 1,040% increase. Thirteen of these notices specifically mention homicidal ideation or thoughts of harming others. Specific examples include homicidal ideation added to the labeling of extended-release venlafaxine in 2005; a boxed neuropsychiatric warning for bupropion products in 2009 citing hostility, agitation, aggression, psychosis, homicidal ideation, and suicidal events; and a 2023 FDA class-wide warning for central nervous system stimulants stating that "anxiety, psychosis, hostility, aggression, and suicidal or homicidal ideation" have been observed with stimulant abuse or misuse. Esketamine nasal spray labeling instructs patients to seek medical attention for sudden changes in mood or behavior, including acting aggressively or violently, and the antipsychotic aripiprazole lists homicidal ideation as a rare adverse reaction in adults.
The central issue for CCHR is that printing a warning does not ensure a patient has seen, understood, or discussed it with a physician. This concern has also influenced public policy. A 2026 Tennessee law requires toxicology testing for psychiatric and other drugs following specified violent incidents, and CCHR has called for similar laws in every state.
Eastgate emphasized: "Drug labeling now contains warnings and adverse-event information that consumers have a right to know about. While not all individuals taking a prescription psychotropic drug will become violent or suicidal, they should read these warnings and ask questions before agreeing to treatment. Prescribers should explain potentially serious violent and suicidal adverse effects—including those considered rare—and document that the patient was given the information necessary to make an informed decision. A label alone does not ensure informed consent."
Patients are advised not to abruptly stop taking psychiatric drugs; any reduction or discontinuation should be done under medical supervision. CCHR, established in 1969 by the Church of Scientology and Dr. Thomas Szasz, has long advocated for transparent disclosure of known risks and prescriber accountability as fundamental to informed consent.
